TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06050005

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diagnostic test through functional tests and comparison of scales applied to participants in the pre-surgical and post-surgical period.
Description: The protocol is based on the ligamentization stages, since the bibliography relates the ligamentization process with rehabilitation. These stages are necrosis, revascularization, cellular priorities and collagen formation, and different care is required for each stage. Taking these aspects into account, the authors developed recommendations to establish a protocol divided by the evaluation phases of the present work. Users should only move on to the next phase if they achieve the expected results, or that makes the total duration of each protocol vary from user to user. tests and scales will be evaluated before surgery, after 6 weeks of surgery and at the end of treatment.
Study: NCT06281574

Intervention type: PROCEDURE
Intervention: Questionnaires
Description: To assess the shoulder function, the following questionnaires will be used:~The validated Dutch translation of the Oxford Shoulder Score (OSS) The validated Dutch translation of the Simple Shoulder Test (SST) The Subjective Shoulder Value (SVV) To assess the work ability patients will use the validated Dutch work-related questionnaire for upper extremity disorders (WORQ-UP)
Study: NCT04518228

Intervention type: DRUG
Intervention: Tenofovir alafenamide (TAF)
Description: Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants

Intervention type: DRUG
Intervention: Cabotegravir (CAB)
Description: Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants

Intervention type: DRUG
Intervention: Dolutegravir (DTG)
Description: Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants

Intervention type: DRUG
Intervention: Atazanavir/ritonavir (ATV/r)
Description: Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants

Intervention type: DRUG
Intervention: Atazanavir/ritonavir (ATV/r)
Description: Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants

Intervention type: DRUG
Intervention: Darunavir/ritonavir (DRV/r)
Description: Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants

Intervention type: DRUG
Intervention: Darunavir/ritonavir (DRV/r)
Description: Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
Study: NCT05054049

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interventional Diagnostic Device Arm
Description: Point of care testing venous blood diagnostic device.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Usual care provided to patient without use of point of care testing device
Study: NCT05050981

Intervention type: DRUG
Intervention: Hormone replacement therapy
Description: Hormone replacement therapy: menopause hormone therapy with estrogen-only or oestrogen-progestin.

Intervention type: DRUG
Intervention: Selective serotonin reuptake inhibitors
Description: Selective serotonin reuptake inhibitors: anyone in the category, e.g.: fluoxetine, sertraline, etc.
Study: NCT05922488

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical cord milking
Description: Umbilical cord milking : uncut umbilical cord and squeeze it from the placenta several times toward the infant usually within 20 seconds.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: delayed cord clamping
Description: delayed cord clamping: delivery the delivering obstetrician will wait at least 60 s before clamping the umbilical cord
Study: NCT06013930

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: External Qigong
Description: External Qigong will be facilitated by a seasoned Qigong practitioner. The Qigong practitioner will assist participants in learning how to use the healing powers of their bodies to decrease feelings of anxiety and/or depression

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation
Description: Mindfulness meditation will be facilitated by a seasoned mindfulness practitioner. Participants will be guided through a meditation designed to help increase a sense of interconnectedness among their college community. They will also learn how to deconstruct feelings of anxiety and/or depression into sensory, emotional, cognitive, and behavioral components.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: In the psychoeducation arm, participants will receive information related to managing anxiety and/or depression through a recorded presentation. Participants will learn about stress-management techniques to help reduce symptoms of anxiety and/or depression. They will also receive information on resources that could be helpful in treating anxiety and/or depression.
Study: NCT05806931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102, oxaliplatin, irinotecan with bevacizumab
Description: Participants will be treated with the study drugs until radiological evidence of disease progression or until treatment discontinuation secondary to adverse events. TAS-OX alternating with TAS-IRI (sequential TASOXIRI) with Bevacizumab, in the treatment of mCRC.
Study: NCT05787067

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Belief Model-Based Mobile Online Training
Description: Health Belief Model-Based Mobile Online Training
Study: NCT06480604

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Participants in this arm will receive a daily dose of 2x10\^9 Colony Forming Units (CFU) of a multi strain probiotic (live bacterium), corresponding to 2 capsules once daily, for 6 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in this arm will receive an equivalent placebo for the duration of the study (6 months).
Study: NCT05553314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: patients randomized to carvedilol group will receive carvedilol-SR.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: patients randomized to placebo group will receive placebo.
Study: NCT04945512

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epidural Analgesia
Description: In the anesthesia preparation room, an epidutal catheter will be placed with a toue needle through the L4-5 spinal space. After induction of general anesthesia, 10 ml of 0.25% bupivacaine will be injected through the epidural catheter.Afterwards, peroperative and postoperative analgesia will be provided with epidural PCA.
Study: NCT05893355

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acupressure group
Description: Application to Acupressure Group~* Participants in this group will be interviewed for the first time at postpartum week 1, and for the second time between 4-6 weeks postpartum. The application will be explained and a voluntary consent form will be signed.~* Participant Information Form will be filled in by the researcher by face-to-face interview.~* The VAS, which will be applied to the puerperant women for the first time in the first week of the postpartum week and for the second time between the 4th-6th weeks, will be filled by the participant just before the application to evaluate the back pain.~* The VAS Evaluating Back Pain after the application will be filled in by the participant.~* The participant will be informed that the study has been completed.
Study: NCT05047068

Intervention type: DEVICE
Intervention: OCS Heart System
Description: The TransMedics® OCS Heart System is a portable system available for ex-vivo maintenance of a donor heart in a metabolically active and beating state.~The OCS Heart System's innovative technology was designed to comprehensively overcome the historical limitations of cold storage. The OCS Heart System expands the utilization of donor hearts by enabling the use of donor hearts deemed unsuitable for procurement and transplantation at initial evaluation due to limitations of cold static cardioplegic preservation.

Intervention type: DEVICE
Intervention: OCS Heart System
Description: The TransMedics® OCS Heart System is a portable system available for ex-vivo maintenance of a donor heart in a metabolically active and beating state.~The OCS Heart System's innovative technology was designed to comprehensively overcome the historical limitations of cold storage. The OCS Heart System expands the utilization of donor hearts by enabling the use of donor hearts deemed unsuitable for procurement and transplantation at initial evaluation due to limitations of cold static cardioplegic preservation.

Intervention type: DEVICE
Intervention: OCS Heart System
Description: The TransMedics® OCS Heart System is a portable system available for ex-vivo maintenance of a donor heart in a metabolically active and beating state.~The OCS Heart System's innovative technology was designed to comprehensively overcome the historical limitations of cold storage. The OCS Heart System expands the utilization of donor hearts by enabling the use of donor hearts deemed unsuitable for procurement and transplantation at initial evaluation due to limitations of cold static cardioplegic preservation.
Study: NCT05869760

Intervention type: OTHER
Intervention: Carotenoid Intake
Description: Carotenoid intake calculated from food diary records reported by guardians.

Intervention type: OTHER
Intervention: Serum carotenoid concentrations
Description: Serum carotenoid concentrations measured by HPLC.
Study: NCT05933616

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device: Sokru device
Description: Different induced glycaemic states in people living with diabetes (PwD).
Study: NCT06160245

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise therapy
Description: core stabilization exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise therapy
Description: core stabilization exercises
Study: NCT06040255

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone, prednisolone, prednisone
Description: Any generic or brand-name methylprednisolone at the appropriate dose may be used. Likewise, any generic or brand-name prednisolone, or prednisone, at the appropriate dose may be used.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone, prednisolone, prednisone
Description: Any generic or brand-name methylprednisolone at the appropriate dose may be used. Likewise, any generic or brand-name prednisolone, or prednisone, at the appropriate dose may be used.
Study: NCT05205863

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cofact
Description: Human prothrombin complex concentrate

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cofact
Description: Human prothrombin complex concentrate

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Cofact
Description: Human prothrombin complex concentrate
Study: NCT04847687

Intervention type: DRUG
Intervention: methylprednisolone
Description: Patients who are hospitalized with a pre-diagnosis of severe COVID-19 pneumonia and who are started on methylprednisolone will be divided into two groups according to the drug dose. Groups will be compared in terms of length of hospital stay, intensive care needs and prognosis.

Intervention type: DRUG
Intervention: methylprednisolone
Description: Patients who are hospitalized with a pre-diagnosis of severe COVID-19 pneumonia and who are started on methylprednisolone will be divided into two groups according to the drug dose. Groups will be compared in terms of length of hospital stay, intensive care needs and prognosis.
Study: NCT06496724

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Albumin paclitaxel/neutrophil drug
Description: Isolate the patients' autologous neutriphil cells, induce and culture them with albumin paclitaxel in vitro. The final product for Albumin paclitaxel/neutrophil drug.
Study: NCT06352073

Intervention type: DRUG
Group type: OTHER
Intervention: Dupilumab
Description: 300mg weekly subcutaneous injection
Study: NCT06121752

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic submucosal dissection
Description: Endoscopic resection is recommended for the management of small DNETs measuring ≤10 mm. Various endoscopic techniques have been utilized for the resection of DNETs including endoscopic mucosal resection (EMR), band ligation assisted EMR, endoscopic submucosal dissection (ESD). However, the published studies report a high rate of histologically incomplete resection even with ESD. More recently, device assisted endoscopic full thickness resection (EFTR) has emerged as a safe and effective resection modality in cases with upper and lower gastrointestinal (GI) mucosal as well as submucosal lesions. There is limited data on the outcomes of EFTR in cases with DNETs.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EFTR
Description: Initially, the lesion will be marked circumferentially using the FTRD probe available with the device (Forced Coag, E1, 20W). Subsequently, wire guided balloon dilatation of the pyloric channel will be performed.~The device will be mounted over a therapeutic channel gastroscope and negotiated across the cricopharynx over the guidewire with or without assistance of dilating balloon available with the device.~After reaching the target site, the lesion will be pulled withing the FTRD cap with the help of grasping forceps and gentle suctioning.~The clip will be fired after ensuring the entry of the lesion inside the cap, the premounted snare closed and electrocautery activated to cut the grasped tissue (HighCut 200W, Effect 4).
Study: NCT05882370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: Patients were treated with TIPS plus Cadonilimab (10mg/kg, intravenously, d1, Q3W) to a maximum total cycle of 18 unless any evidence of disease progression or unacceptable side effects.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transjugular intrahepatic portosystemic shunt (TIPS)
Description: transjugular intrahepatic portosystemic shunt (TIPS)
Study: NCT05944289

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: a four-week workshop based on the principles and procedures of Acceptance and Commitment Therapy

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Caregiver Support Group
Description: Caregiver support group to run parallel to the ACT intervention group.
Study: NCT05852184

Intervention type: OTHER
Intervention: Hb Scope APP
Description: The study intervention is the Hb Scope APP, a camera-based real-time Hb estimation tool using a data collection function and a machine learning-based algorithm to analyze the image of HD tubing and output the estimated Hb value.~Our proposed Hb Scope APP can provide a non-invasive and real-time estimation of Hb level for detecting the alarming Hb status (i.e., \<=10 g/dL) during every HD session. The software is for information management purposes only and is not intended for diagnostic use.

Intervention type: OTHER
Intervention: Hb Scope APP
Description: The study intervention is the Hb Scope APP, a camera-based real-time Hb estimation tool using a data collection function and a machine learning-based algorithm to analyze the image of HD tubing and output the estimated Hb value.~Our proposed Hb Scope APP can provide a non-invasive and real-time estimation of Hb level for detecting the alarming Hb status (i.e., \<=10 g/dL) during every HD session. The software is for information management purposes only and is not intended for diagnostic use.

Intervention type: OTHER
Intervention: Hb Scope APP
Description: The study intervention is the Hb Scope APP, a camera-based real-time Hb estimation tool using a data collection function and a machine learning-based algorithm to analyze the image of HD tubing and output the estimated Hb value.~Our proposed Hb Scope APP can provide a non-invasive and real-time estimation of Hb level for detecting the alarming Hb status (i.e., \<=10 g/dL) during every HD session. The software is for information management purposes only and is not intended for diagnostic use.
Study: NCT05636644

Intervention type: DRUG
Intervention: Taxol
Description: All patients received TAC regimen: both groups received AC (epirubicin 75 mg/m ² and cyclophosphamide 500mg/m ²)， Group A was treated with docetaxel for 6 cycles every 3 weeks (75 mg/m on the first day ²)； Group B received six cycles of nab paclitaxel (125 mg/m ²)， every 3 weeks is a course of treatment.
Study: NCT06000332

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InogenOne Rove 6 Portable Oxygen Concentrator
Description: overnight use of Portable Oxygen Concentrator, 6 hours minimum
Study: NCT05668975

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Inspiratory Muscle Training
Description: A mechanical pressure threshold loading device (POWERbreathe, POWERbreathe International Ltd, UK) will be used for the training.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: A mechanical pressure threshold loading device (POWERbreathe, POWERbreathe International Ltd, UK) will be used for the training.
Study: NCT04993950

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sustained natural apophyseal glides
Description: SNAGS will be applied in flexion, extension and rotation for a few seconds with 3 repetitions on the first day and 10 repetitions from the next visit.
Study: NCT06144892

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proactive Therapy
Description: Uses AI to make predictions and preventions of future apneic events.
Study: NCT06539182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DZD8586
Description: Daily oral dose of DZD8586 at 25 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DZD8586
Description: Daily oral dose of DZD8586 at 50 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DZD8586
Description: Daily oral dose of DZD8586 at 75 mg.
Study: NCT05708274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPH + hand training
Description: Following a 10-minute rest after baseline measurements a single dose pharmacological agent or placebo will be administered, in blinded fashion, with up to 180 mL of noncarbonated water, on an empty stomach (minimum 2 hours without food). After capsule ingestion, participants will spend 50 minutes performing hand task-oriented training, resting for 10 minutes before undertaking post-intervention outcome measurements.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD-LD + hand training
Description: Following a 10-minute rest after baseline measurements a single dose pharmacological agent or placebo will be administered, in blinded fashion, with up to 180 mL of noncarbonated water, on an empty stomach (minimum 2 hours without food). After capsule ingestion, participants will spend 50 minutes performing hand task-oriented training, resting for 10 minutes before undertaking post-intervention outcome measurements.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATX + hand training
Description: Following a 10-minute rest after baseline measurements a single dose pharmacological agent or placebo will be administered, in blinded fashion, with up to 180 mL of noncarbonated water, on an empty stomach (minimum 2 hours without food). After capsule ingestion, participants will spend 50 minutes performing hand task-oriented training, resting for 10 minutes before undertaking post-intervention outcome measurements.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + hand training
Description: Following a 10-minute rest after baseline measurements a single dose pharmacological agent or placebo will be administered, in blinded fashion, with up to 180 mL of noncarbonated water, on an empty stomach (minimum 2 hours without food). After capsule ingestion, participants will spend 50 minutes performing hand task-oriented training, resting for 10 minutes before undertaking post-intervention outcome measurements.
Study: NCT04993950

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sustained natural apophyseal glides
Description: SNAGS will be applied in flexion, extension and rotation for a few seconds with 3 repetitions on the first day and 10 repetitions from the next visit.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SNAGS with thoracic postural correction techniques
Description: thoracic extension in sitting, Wall angle stretch and Corner stretch, while the therapist-facilitated stretches will be seated mid-thoracic stretch and prone mid thoracic stretch. Stretches will be maintained for 15-20 seconds with 10 repetitions of each stretch per session

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SNAGS with thoracic postural correction techniques
Description: thoracic extension in sitting, Wall angle stretch and Corner stretch, while the therapist-facilitated stretches will be seated mid-thoracic stretch and prone mid thoracic stretch. Stretches will be maintained for 15-20 seconds with 10 repetitions of each stretch per session
Study: NCT06242236

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The respiratory effort parameters guide sedative dosage.
Description: The intervention involves the measurement of respiratory effort using P0.1 and Pocc then calculating to dynamic transpulmonary pressure swing (Predicted ΔPL) to adjust sedative drug dosage.
Study: NCT05320458

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation
Description: 1-Pulmonary Rehabilitation: Pulmonary rehabilitation program was applied at 40-60% of submaximal heart rate, 3 days a week for a total of 8 weeks. Diaphragmatic breathing, pursed lip breathing and segmental breathing exercises were practiced with the patients in the company of a physiotherapist. Walking and aerobic exercise training was given.
Study: NCT04702555

Intervention type: DRUG
Intervention: VTS-K
Description: An oral combination drug of VTS-Aspirin and ketamine (VTS-K)
Study: NCT04398719

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: [11C]PBR28
Description: The radiotracer, \[11C\]PBR28, will be administered at the beginning of each PET scan
Study: NCT04744155

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-Level Intervention
Description: Behavioral intervention that assesses uptake of contraception and seeks follow-up care.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Standard of Care
Description: Behavioral intervention that assesses uptake of contraception from follow-up care.